11 drug(s) with this reaction
5,272 total reports
Dyspnoea has been reported as an adverse reaction across 11 drug(s) manufactured by Chattem Inc in the FDA Adverse Event Reporting System (FAERS) database. A combined total of 5,272 adverse event reports mention dyspnoea in connection with Chattem Inc products.
This page provides a breakdown of which Chattem Inc drugs are most commonly associated with dyspnoea, along with report counts and links to detailed safety analyses for each medication. Understanding which drugs from a single manufacturer share a common adverse reaction can help patients and healthcare providers identify potential class-wide safety patterns.
The following Chattem Inc drugs have dyspnoea listed in their FDA adverse event reports, sorted by report count:
In addition to dyspnoea, the following adverse reactions have been reported across Chattem Inc's drug portfolio:
11 drug(s) manufactured by Chattem Inc have dyspnoea listed in their FDA adverse event reports: LIDOCAINE, MENTHOL, TRIAMCINOLONE ACETONIDE, LEVOCETIRIZINE DIHYDROCHLORIDE, FEXOFENADINE HYDROCHLORIDE, MENTHOL, and others.
There are a combined 5,272 reports of dyspnoea across 11 Chattem Inc drug(s) in the FDA adverse event database.